News from intarcia therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 28, 2012, 09:30 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

 Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous...

Apr 02, 2012, 09:05 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer

Intarcia Therapeutics, Inc. today announced that its Board of Directors has appointed Kurt Graves to the position of Chairman,...

Mar 27, 2012, 13:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer

 Intarcia Therapeutics, Inc. today announced the appointment of Michelle Baron, MD, FACE, to the position of Vice President...

Oct 21, 2011, 15:26 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the signing of a letter of intent with Quintiles, the world's leading biopharmaceutical services...

Sep 14, 2011, 12:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon

Intarcia Therapeutics, Inc. announced today the presentation of final 48-week results from a phase 2 clinical study of ITCA 650 (DUROS®...

Sep 12, 2011, 08:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes

Intarcia Therapeutics, Inc. announced today the presentation of three clinical abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery...

Jun 28, 2011, 12:45 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS®...

Jan 04, 2011, 15:07 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference

Intarcia Therapeutics, Inc. today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will present at the 29th Annual JP...

Nov 11, 2010, 16:15 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference

Intarcia Therapeutics. Inc today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will be presenting at the Lazard Capital...

Sep 22, 2010, 11:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous...

Sep 16, 2010, 14:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals

The board of directors of Intarcia Therapeutics, Inc. ("Intarcia," the "Company") today announced the appointment of Kurt Graves as executive...

Jun 28, 2010, 10:30 ET

Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of...

Nov 06, 2009, 09:30 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the...

Sep 30, 2009, 10:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference

Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery...

Sep 17, 2009, 07:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650...

Jun 08, 2009, 08:44 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day...

May 27, 2009, 10:46 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today...

Apr 24, 2009, 10:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today announced...

Jun 06, 2007, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

FierceBiotech Names Intarcia Therapeutics as One of the 'Fierce 15' Biotech Companies of 2007

EMERYVILLE, Calif., June 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that it has been named to the annual FierceBiotech...

May 21, 2007, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

WASHINGTON, May 21 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of...